First Manhattan’s Harmony Biosciences HRMY Stock Holding History

First Manhattan’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-153,673	Closed	-$7.48M	–	1602
2022 Q1	$7.48M	Buy	+153,673	New	+$6.27M	0.02%	203

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan's HRMY Position: Q2 2022 in Review

First Manhattan sold out of Harmony Biosciences (HRMY) in Q2 2022, closing a stake of 153,673 shares — an estimated $7.48M sold.

First Manhattan first reported a position in HRMY in Q1 2022 and held it in 1 quarter. The position peaked at $7.48M in Q1 2022. 183 funds tracked by Wall St. Rank hold HRMY as of Q2 2022.

First Manhattan reported no remaining Harmony Biosciences position as of Q2 2022 after selling out during the quarter.
First Manhattan sold 153,673 Harmony Biosciences shares in Q2 2022, an estimated $7.48M.
First Manhattan first reported a position in Harmony Biosciences in Q1 2022 and held it in 1 quarter.
First Manhattan's Harmony Biosciences position peaked at $7.48M in Q1 2022.
183 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2022.

Based on First Manhattan's 13F filing for Q2 2022, filed 15 Aug 2022.